ARTLARTELO BIOSCIENCES, INC.vs its industry peers
A metric-by-metric comparison of ARTELO BIOSCIENCES, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTLThis | $18M#8 | — | 3.6x#13 | — | — | -31.1%#12 | — | -257.7%#13 | — | — | -97.0%#15 | — |
| COCP | $21M#1 | — | 20.6x#16 | 10.7x#6 | -69.3%#7 | 49.5%#2 | -447.8%#5 | -845.9%#16 | -20.4%#1 | 3#2 | -15.2%#3 | — |
| AYTU | $21M#2 | — | 0.6x#3 | 0.3x#1 | 1.8%#4 | 14.4%#6 | -11.8%#1 | -38.6%#3 | -41.4%#2 | 4#1 | -15.7%#4 | — |
| RKTO | $20M#4 | — | 2.4x#10 | — | — | -52.3%#15 | — | -152.0%#10 | — | — | -53.6%#10 | — |
| MRKR | $20M#5 | — | 1.6x#6 | 5.5x#3 | -46.2%#6 | -13.3%#9 | -363.5%#4 | -100.0%#8 | -1413.6%#7 | — | 18.6%#2 | — |
| SHPH | $20M#3 | 349.0x#4 | 6.1x#15 | — | — | -28.2%#11 | — | -350.3%#15 | -507.7%#5 | — | -90.3%#13 | — |
| ALLR | $19M#6 | 0.0x#1 | 5.4x#14 | 59.7x#8 | — | 54.2%#1 | -3939.1%#7 | -317.6%#14 | — | — | -18.9%#5 | — |
| BFRI | $18M#7 | — | 3.1x#11 | 0.4x#2 | 11.7%#2 | 40.7%#3 | -27.2%#2 | -176.9%#11 | -712.4%#6 | — | 41.5%#1 | — |
| PTN | $18M#9 | 89.5x#3 | 1.7x#7 | — | -100.0%#10 | -41.8%#13 | — | 163.3%#2 | -2281.5%#8 | — | — | — |
| LPCN | $17M#10 | — | 0.8x#4 | 8.8x#5 | -82.3%#8 | -96400.0%#16 | -524.7%#6 | -44.2%#5 | -52.6%#3 | — | -26.6%#7 | — |
| KTTA | $16M#11 | — | 0.3x#2 | 33.7x#7 | 3130.4%#1 | -46.9%#14 | -4286.7%#8 | -41.0%#4 | — | — | -33.4%#8 | — |
| CTXR | $16M#12 | — | 0.2x#1 | 180.5x#10 | 0.0%#5 | -0.8%#7 | -42806.2%#10 | -59.7%#6 | — | — | -49.9%#9 | — |
| LSTA | $16M#13 | — | 1.9x#9 | 94.3x#9 | -83.0%#9 | 17.0%#5 | -10711.2%#9 | -201.2%#12 | — | 3#2 | -22.3%#6 | — |
| CYCN | $16M#14 | — | 3.1x#12 | 7.6x#4 | 3.7%#3 | -15.4%#10 | -239.8%#3 | -69.4%#7 | -69.1%#4 | — | -77.9%#11 | — |
| ANEB | $15M#15 | — | 1.9x#8 | — | — | -3.5%#8 | — | -106.9%#9 | — | — | -85.1%#12 | — |
| MBRX | $15M#16 | 0.1x#2 | 1.3x#5 | — | — | 28.8%#4 | — | 289.6%#1 | — | — | -92.5%#14 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice